福瑞达(600223) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 1,272,172,649.79, representing a decrease of 14.17% compared to the same period last year[3]. - Net profit attributable to shareholders increased by 95.09% to CNY 129,333,003.46, primarily due to the recognition of investment income from the first batch of asset disposals in the real estate sector[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 75.99% to CNY 15,188,793.41, mainly due to lower gross margins from health real estate projects[8]. - Basic earnings per share rose by 85.71% to CNY 0.13, while diluted earnings per share increased by 116.67% to CNY 0.13[3]. - Total revenue for Q1 2023 was CNY 1,272,172,649.79, a decrease of 14.15% compared to CNY 1,482,210,648.61 in Q1 2022[21]. - Net profit for Q1 2023 reached CNY 154,054,941.52, an increase of 131.76% compared to CNY 66,403,453.14 in Q1 2022[22]. - Earnings per share for Q1 2023 were CNY 0.13, up from CNY 0.07 in Q1 2022[22]. Asset and Liability Management - The company's total assets decreased by 78.74% to CNY 12,432,487,828.70, largely due to the asset disposals in the real estate sector[4]. - As of March 31, 2023, total assets amounted to RMB 12.432 billion, with net assets attributable to the parent company at RMB 3.846 billion[12]. - The total assets as of March 31, 2023, were CNY 12,432,487,828.70, a decrease from CNY 58,473,809,904.37 at the end of 2022[19]. - Total liabilities as of March 31, 2023, were CNY 7,879,885,400.20, down from CNY 52,906,919,273.56 at the end of 2022[19]. - The company’s non-current assets totaled CNY 1,804,545,779.04 as of March 31, 2023, compared to CNY 2,845,062,458.13 at the end of 2022[19]. Cash Flow Analysis - The net cash flow from operating activities was CNY 94,445,215.80, with a significant increase compared to the previous year, attributed to reduced operational expenditures in the health industry[8]. - In Q1 2023, the company's operating cash inflow was CNY 1,715,420,520.76, a decrease of 23.6% compared to CNY 2,247,548,715.53 in Q1 2022[25]. - The net cash flow from operating activities turned positive at CNY 94,445,215.80, compared to a negative CNY 349,836,200.78 in the same period last year[25]. - The total cash inflow from investment activities was CNY 1,396,563,999.17, a significant increase from CNY 21,740,961.75 in Q1 2022[26]. - The net cash flow from investment activities was CNY 1,343,160,623.97, compared to a negative CNY 82,416,623.05 in Q1 2022[26]. - Cash inflow from financing activities totaled CNY 1,325,561,303.83, down from CNY 2,272,576,311.79 in Q1 2022[26]. - The net cash flow from financing activities decreased to CNY 69,692,665.62 from CNY 375,034,442.92 in the previous year[26]. - The company's cash and cash equivalents decreased from RMB 4.318 billion at the end of 2022 to RMB 3.431 billion by March 31, 2023[17]. - The company's cash and cash equivalents at the end of Q1 2023 were CNY 3,144,465,321.77, an increase from CNY 2,189,628,448.26 at the end of Q1 2022[26]. Business Segments Performance - The pharmaceutical segment reported revenue of RMB 143 million in Q1 2023, a year-on-year increase of 59.21%, with a gross margin of 56.40%[12]. - The cosmetics segment generated revenue of RMB 473 million in Q1 2023, reflecting a year-on-year growth of 12.68% and a gross margin of 62.86%[13]. - The real estate segment recorded a contracted sales amount of RMB 705 million in Q1 2023, a decrease of 9.26% year-on-year, with a contracted area of 62,500 square meters, down 20.93%[14]. - The company launched 23 new cosmetic products in Q1 2023, enhancing its research and development capabilities[13]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 45,762[9]. - The company’s major shareholder, Shandong Provincial Commercial Group, holds 51.62% of the total share capital, with 46.21% held through its own securities account[11]. Strategic Initiatives - The company completed the first batch of asset disposals involving six target companies, which will no longer be included in the consolidated financial statements[4]. - The remaining two target companies are expected to complete their asset disposals by October 31, 2023, marking the company's exit from the real estate development business[4]. - The company plans to focus on new product development and market expansion strategies in the upcoming quarters[20].